Ayala Pharmaceuticals, Inc. (ADXS)
(Delayed Data from OTC)
$0.25 USD
-0.02 (-7.41%)
Updated Jun 7, 2024 02:16 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Ayala Pharmaceuticals, Inc. [ADXS]
Reports for Purchase
Showing records 81 - 96 ( 96 total )
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Novel immunological treatment for cancer acts as a differentiator
Provider: STONEGATE CAPITAL MARKETS
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Reported results for its Q1F10 via its 10Q filing.
Provider: STONEGATE CAPITAL MARKETS
Analyst: RODRIGUEZ M
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Reported results for its Q4 and fiscal year end
Provider: STONEGATE CAPITAL MARKETS
Analyst: RODRIGUEZ M